{"slug":"retatrutide","seoKey":"retatrutide","inn":"retatrutide","displayName":"Retatrutide","codes":["LY3437943","LY-3437943"],"synonyms":["GIP/GLP-1/glucagon receptor triple agonist","GGG tri-agonist","retatrutide sodium (sodium salt, UNII LQ42M82ZU6, PubChem CID 171934787)"],"legalClass":"investigational","identifiers":{"cas":"2381089-83-2","unii":"NOP2Y096GV","chemblId":"CHEMBL5095485","wikidataQid":"Q120468350","sequence":"YAQGTFTSDYSILLDKKAQAAFIEYLLEGGPSSGAPPPS"},"approvals":[{"market":"US","status":"investigational","note":"Not approved; investigational medicinal product in phase 3. No entry found in Drugs@FDA on 2026-09-06. A pre-approval expanded access protocol exists and is not an approval.","source":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:retatrutide"},{"market":"EU","status":"investigational","note":"Not approved; no centralised marketing authorisation. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=retatrutide"},{"market":"DE","status":"investigational","note":"Not approved; Germany follows the centralised EU authorisation, which does not exist for this substance. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=retatrutide"},{"market":"UK","status":"investigational","note":"Not approved; no marketing authorisation. No entry found in the MHRA product database on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=retatrutide"},{"market":"AU","status":"investigational","note":"Not approved; no entry found in the Australian Register of Therapeutic Goods on 2026-09-06.","source":"https://www.tga.gov.au/resources/artg"},{"market":"CA","status":"investigational","note":"Not approved; no drug identification number. No entry found in the Drug Product Database on 2026-09-06.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=retatrutide"},{"market":"CH","status":"investigational","note":"Not approved; no entry found in the Swiss medicinal product information on 2026-09-06.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"phase3","strongestEvidence":"rct_phase2","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT03841630","name":"First-in-human single ascending dose study in healthy participants","phase":"Phase 1","n":45,"status":"COMPLETED"},{"nct":"NCT04881760","name":"Phase 2 obesity study (48 weeks)","phase":"Phase 2","n":338,"status":"COMPLETED"},{"nct":"NCT04867785","name":"Phase 2 study in type 2 diabetes (active-controlled against dulaglutide)","phase":"Phase 2","n":281,"status":"COMPLETED"},{"nct":"NCT05936151","name":"Phase 2 study of kidney function in obesity and chronic kidney disease","phase":"Phase 2","n":146,"status":"COMPLETED"},{"nct":"NCT05929066","name":"TRIUMPH-1","phase":"Phase 3","n":2335,"status":"COMPLETED"},{"nct":"NCT05929079","name":"TRIUMPH-2","phase":"Phase 3","n":1152,"status":"COMPLETED"},{"nct":"NCT05882045","name":"TRIUMPH-3","phase":"Phase 3","n":1946,"status":"COMPLETED"},{"nct":"NCT05931367","name":"TRIUMPH-4","phase":"Phase 3","n":445,"status":"COMPLETED"},{"nct":"NCT06662383","name":"TRIUMPH-5 (head-to-head against tirzepatide)","phase":"Phase 3","n":800,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT06859268","name":"TRIUMPH-6 (maintenance of weight reduction)","phase":"Phase 3","n":643,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT07035093","name":"TRIUMPH-7 (chronic low back pain)","phase":"Phase 3","n":586,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT06383390","name":"TRIUMPH-Outcomes (cardiovascular and kidney endpoints)","phase":"Phase 3","n":10000,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT06354660","name":"TRANSCEND-T2D-1","phase":"Phase 3","n":537,"status":"COMPLETED"},{"nct":"NCT06260722","name":"TRANSCEND-T2D-2 (comparison against semaglutide)","phase":"Phase 3","n":1250,"status":"ACTIVE_NOT_RECRUITING"},{"nct":"NCT06297603","name":"TRANSCEND-T2D-3 (renal impairment)","phase":"Phase 3","n":320,"status":"ACTIVE_NOT_RECRUITING"}],"sameAs":["https://www.wikidata.org/wiki/Q120468350","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5095485/","https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13769"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"Retatrutide: what the trials show, status and safety","summary":"Retatrutide is an experimental peptide that switches on three hormone systems at the same time. In a mid-stage trial, participants lost 24.2% of their body weight over 48 weeks. The later, larger trials report bigger losses, but so far only through press releases from the manufacturer. No medicines authority has approved it, and no completed trial shows that it prevents heart attacks or strokes.","updated":"2026-09-06","url":"https://mypep.app/peptides/retatrutide"}